Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y
Department of Pathology (II), Kanazawa University School of Medicine, Kanazawa, Japan.
Histopathology. 1999 Sep;35(3):230-40. doi: 10.1046/j.1365-2559.1999.00705.x.
The significance of molecular and genetic alterations of p53 and ras in the development and progression as well as the histological differentiation of intrahepatic cholangiocarcinoma (ICC) was evaluated.
We examined immunohistochemically ras p21 protein and p53-related products (p53 protein, WAF-1 and mdm-2) in 43 cases of ICC. In addition, point mutations of ras and p53 were examined genetically in selected ICC cases by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and direct sequence analysis. Point mutation of K-ras gene codon 12 was detected in three of 14 cases and one of 15 cases by PCR-RFLP and direct sequence analysis, respectively. Immunoreactivity of ras p21 protein was not detected. Point mutation of p53 was detected in three of 15 cases. p53 protein was immunohistochemically detectable in 33 of 43 cases. Immunoreactivity of p53 was more frequent in well-differentiated and less frequent in poorly differentiated cases. Immunoreactivity of WAF-1 and mdm-2 was seen in 16 and eight of 43 cases, respectively. Both proteins were frequently detected in the cases positive for p53 protein.
These results suggest that dysregulation of ras is involved in at least 20% of ICC and expression of p53 protein is more significantly involved in ICC, particularly in the well and moderately differentiated cases. While some cases of p53 expression may be explainable by point mutation of p53, there may be some epigenetic phenomena that stabilize p53 protein in ICC. That is, wild type p53 may be stabilized and then detectable by forming complexes with other molecules of p53 downstream effector genes, such as WAF-1 and mdm-2.
评估p53和ras的分子及基因改变在肝内胆管癌(ICC)发生、发展以及组织学分化中的意义。
我们对43例ICC病例进行了ras p21蛋白和p53相关产物(p53蛋白、WAF-1和mdm-2)的免疫组织化学检查。此外,通过聚合酶链反应-限制性片段长度多态性(PCR-RFLP)和直接测序分析,对部分ICC病例进行了ras和p53的点突变基因检测。通过PCR-RFLP和直接测序分析,分别在14例中的3例和15例中的1例检测到K-ras基因密码子12的点突变。未检测到ras p21蛋白的免疫反应性。在15例中的3例检测到p53点突变。43例中的33例通过免疫组织化学检测到p53蛋白。p53的免疫反应性在高分化病例中更常见,在低分化病例中较少见。43例中的16例和8例分别检测到WAF-1和mdm-2的免疫反应性。这两种蛋白在p53蛋白阳性病例中经常被检测到。
这些结果表明,ras失调至少参与了20%的ICC,p53蛋白表达更显著地参与了ICC,特别是在高分化和中分化病例中。虽然部分p53表达病例可能可以用p53点突变来解释,但在ICC中可能存在一些使p53蛋白稳定的表观遗传现象。也就是说,野生型p53可能通过与p53下游效应基因的其他分子(如WAF-1和mdm-2)形成复合物而被稳定,进而被检测到。